Primary Hyperoxaluria (PH) - Epidemiology Forecast to 2027

October 2018 | 73 pages | ID: P544DE77D6EEN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight’s ‘Primary Hyperoxaluria (PH) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Primary Hyperoxaluria (PH) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

GEOGRAPHY COVERED

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Primary Hyperoxaluria (PH)

The Primary Hyperoxaluria (PH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Primary Hyperoxaluria (PH) are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Primary Hyperoxaluria (PH) Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, Type specific diagnosed prevalent cases and Age-Specific diagnosed prevalent cases) scenario of Primary Hyperoxaluria (PH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total diagnosed prevalent population of Primary Hyperoxaluria (PH) was found to be 3,714 in the year 2016 in 7MM.

REPORT SCOPE

• The report covers detailed overview of Primary Hyperoxaluria (PH) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Primary Hyperoxaluria (PH) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by Type specific diagnosed prevalent cases (PH Type 1, Type 2, Type 3 and unclassified) and Age-Specific diagnosed prevalent cases in 7MM

KEY STRENGTHS

• 10 Year Forecast of Primary Hyperoxaluria (PH)
• 7MM Coverage
• Total Prevalent Cases of PH
• Prevalent Cases according to segmentation: Type specific diagnosed prevalent cases and Age-Specific diagnosed prevalent cases

KEY ASSESSMENTS

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. DISEASE BACKGROUND AND OVERVIEW: PRIMARY HYPEROXALURIA (PH)

2.1. Introduction
2.2. Symptoms
2.3. Genetic basis of Primary Hyperoxaluria
2.4. Classification
2.5. Etiology
2.6. Pathophysiology
2.7. Diagnosis
2.8. Management

3. EPIDEMIOLOGY AND PATIENT POPULATION

3.1. Key Findings
3.2. Forecast Methodology

4. 7MM TOTAL DIAGNOSED PREVALENT PATIENT POPULATION OF PRIMARY HYPEROXALURIA

5. COUNTRY WISE-EPIDEMIOLOGY OF PRIMARY HYPEROXALURIA

5.1. United States
  5.1.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the United States
  5.1.2. Type Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in the United States
  5.1.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in United States
5.2. EU5 Countries
5.3. Germany
  5.3.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Germany
  5.3.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Germany
  5.3.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in Germany
5.4. France
  5.4.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in France
  5.4.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in France
  5.4.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in France
5.5. Italy
  5.5.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Italy
  5.5.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Italy
  5.5.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in Italy
5.6. Spain
  5.6.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Spain
  5.6.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Spain
  5.6.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in Spain
5.7. United Kingdom
  5.7.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the United Kingdom
  5.7.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United Kingdom
  5.7.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in United Kingdom
5.8. Japan
  5.8.1. Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Japan
  5.8.2. Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Japan
  5.8.3. Age Specific Diagnosed Prevalent Population of Primary Hyperoxaluria in Japan

6. APPENDIX

6.1. Report Methodology

7. DELVEINSIGHT CAPABILITIES

8. DISCLAIMER

9. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1: Comparison between Primary and Secondary hyperoxaluria
Table 2: Patient characteristics at last study follow-up; patients diagnosed at paediatric age versus adult age in separate columns (PH Type 1)
Table 3: Characteristics of infantile cases of PH1 by genotype
Table 4: Percentage of the most common mutations identified from 222 alleles
Table 5: Comparing the different types of Primary Hyperoxaluria
Table 6: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the 7MM (2016-2027)
Table 7: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the United States (2016-2027)
Table 8: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United States (2016-2027)
Table 9: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United States (2016-2027)
Table 10: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Germany (2016-2027)
Table 11: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Germany (2016-2027)
Table 12: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Germany (2016-2027)
Table 13: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in France (2016-2027)
Table 14: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in France (2016-2027)
Table 15: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in France (2016-2027)
Table 16: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Italy (2016-2027)
Table 17: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Italy (2016-2027)
Table 18: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Italy (2016-2027)
Table 19: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Spain (2016-2027)
Table 20: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Spain (2016-2027)
Table 21: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Spain (2016-2027)
Table 22: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the UK (2016-2027)
Table 23: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in the UK (2016-2027)
Table 24: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in the UK (2016-2027)
Table 25: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Japan (2016-2027)
Table 26: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Japan (2016-2027)
Table 27: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Japan (2016-2027)

List Of Figures

LIST OF FIGURES

Figure 1: Calcium Oxalate deposits in the urinary space and in the renal tissue
Figure 2: Bone Oxalosis
Figure 3: Main routes of glyoxalate metabolism in a human hepatocyte
Figure 4: Metabolism of oxalate and renal outcome in patients with Primary Hyperoxaluria type
Figure 5: Total Diagnosed Prevalent Patient Population of Primary Hyperoxaluria in the 7MM (2016-2027)
Figure 6: Diagnosed Prevalence of Primary Hyperoxaluria in the United States (2016-2027)
Figure 7: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United States (2016-2027)
Figure 8: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United States (2016-2027)
Figure 9: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Germany (2016-2027)
Figure 10: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Germany (2016-2027)
Figure 11: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Germany (2016-2027)
Figure 12: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in France (2016-2027)
Figure 13: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in France (2016-2027)
Figure 14: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in France (2016-2027)
Figure 15: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Italy (2016-2027)
Figure 16: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Italy (2016-2027)
Figure 17: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Italy (2016-2027)
Figure 18: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Spain (2016-2027)
Figure 19: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Spain (2016-2027)
Figure 20: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Spain (2016-2027)
Figure 21: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the UK (2016-2027)
Figure 22: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United Kingdom (2016-2027)
Figure 23: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in the United Kingdom (2016-2027)
Figure 24: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in Japan (2016-2027)
Figure 25: Type Specific Diagnosed Prevalence of Primary Hyperoxaluria in Japan (2016-2027)
Figure 26: Age Specific Diagnosed Prevalence of Primary Hyperoxaluria in Japan (2016-2027)